{Reference Type}: Letter
{Title}: DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
{Author}: Kizhakeyil A;Zaini NBM;Poh ZS;Wong BHS;Loh X;Ng AS;Low ZS;Prasannan P;Gong C;Tan MGK;Nagarajan C;Huang D;Lu PW;Lim JQ;Barrans S;Ong CK;Lim ST;Chng WJ;Follows G;Hodson DJ;Du MQ;Goh YT;Tan SH;Grigoropoulos NF;Verma NK;
{Journal}: Mol Cancer
{Volume}: 20
{Issue}: 1
{Year}: 10 2021 16
{Factor}: 41.444
{DOI}: 10.1186/s12943-021-01437-0
{Abstract}: